The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback